O38: NNZ-2591, a synthetic IGF-1 metabolite analog: Phase 2 clinical trial results for children and adolescents with Pitt Hopkins syndrome

fibrosis were unchanged including patients who stopped ERT.All patients remained healthy, and no severe adverse events were reported after the initial transplant period.All patients showed polyclonal marking of peripheral blood cells and no evidence of secondary malignancies to date.